Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors

US7807681B2 · kind B2 · utility

Assignee

• Wilex AG · DE

Inventors

• Stefan Sperl · Birkenfeld, DE
• Markus Buergle · Munich, DE
• Wolfgang Schmalix · Puchheim, DE
• Katja Wosikowski · Poing, DE
• Bernd Clement · Kiel, DE

Key dates

• Filing date: Apr 18, 2008
• Grant date: Oct 5, 2010
• Expiry date: Apr 18, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K5/06191
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.